Clinical Trials Logo

Neoplasm, Breast clinical trials

View clinical trials related to Neoplasm, Breast.

Filter by:

NCT ID: NCT03756064 Recruiting - Breast Cancer Clinical Trials

Neoadjuvant Study of Pyrotinib in Patients With HER2 Positive Breast Cancer

Start date: August 1, 2019
Phase: N/A
Study type: Interventional

This is a randomized, double-blind multicenter Phase III study for evaluating the efficacy and safety of neoadjuvant pyrotinib and trastuzumab plus docetaxel and Carboplatin versus placebo and trastuzumab plus docetaxel and Carboplatin given as neoadjuvant treatment in HER2 positive early stage or locally advanced breast cancer.

NCT ID: NCT03715686 Recruiting - Clinical trials for Lymph Node Metastases

To Accurately Assess Lymph Node Response to NACT by Wire Localization of Clip-marked Lymph Nodes

Start date: October 20, 2018
Phase: N/A
Study type: Interventional

The investigator developed this protocol to accurately assess lymph node response to neoadjuvant chemotherapy in clinical stage N1 (cN1) breast cancer patients. Accuracy of sentinel lymph node biopsy (SLNB) alone and in combination with the removal of wire-localized-clip-marked nodes will be analyzed. New model to predict lymph node pathological complete remission (pCR) so as to safely avoid axillary lymph node dissection in cN1 breast cancer patients is sought for.

NCT ID: NCT03678883 Active, not recruiting - Cancer Clinical Trials

9-ING-41 in Patients With Advanced Cancers

Start date: January 4, 2019
Phase: Phase 2
Study type: Interventional

GSK-3β is a potentially important therapeutic target in human malignancies. The Actuate 1801 Phase 1/2 study is designed to evaluate the safety and efficacy of 9-ING-41, a potent GSK-3β inhibitor, as a single agent and in combination with cytotoxic agents, in patients with refractory cancers.

NCT ID: NCT03368196 Completed - Neoplasm, Breast Clinical Trials

DS-8201a in Patients With Cancer That Tests Positive for Human Epidermal Growth Factor Receptor 2 (HER2) Protein

Start date: April 2, 2018
Phase: Phase 1
Study type: Interventional

HER2-positive cancer is a cancer that tests positive for a protein called human epidermal growth factor receptor 2 (HER2). HER2 promotes the growth of certain cancer cells. This study will test DS-8201a (trastuzumab deruxtecan), a HER2-targeted antibody and topoisomerase I inhibitor conjugate. The safety and tolerability profile of DS-8201a will be assessed in Chinese patients with certain types of stomach and breast cancer that test positive for HER2. It also will test how DS-8201a moves within the body (pharmacokinetics).